Scott I. Raskin, DO
- Pediatric Neuro-Oncologist, Division of Oncology
- Assistant Professor, UC Department of Pediatrics
- scott.raskin@cchmc.org
- Board Certified
About
Biography
As a pediatric neuro-oncologist, my philosophy is to treat my patients' diseases to the best of my ability and care for them and their families as people, not just a condition to cure. Making sure we are here for families and patients as a whole ensures we’re providing the best possible care.
Initially, I was inspired to become a pediatrician because of my childhood pediatrician's care and experience. As I continued through medical training, I was amazed by children's resiliency and knew I wanted to care for them.
I was drawn to pediatric oncology because it uses the most current advances in healthcare. I also enjoy working with the most remarkable patients and families. Their strength inspires me to work harder every day.
In my research, I am trying to better understand how we can cure pediatric central nervous system (CNS) tumors with poor outcomes. I’m also looking at how to treat relapsed or refractory disease using novel clinical trials or therapies and directly translating this research from the lab.
In my free time, I like to explore parks and spend time outside with my family.
BA: Biology and Spanish Language/Literature, Binghamton University, Binghamton, NY.
DO: Western University of Health Sciences, Pomona, CA.
Internship and Residency: Pediatrics, Miami Children’s Hospital (now Nicklaus Children’s Hospital), Miami, FL.
Fellowship Training: Pediatric Hematology / Oncology / BMT, Children’s National Hospital, Washington, DC; Pediatric Neuro-Oncology, Children’s National Hospital, Washington, DC.
Certifications: Pediatrics, 2016; Pediatric Hematology / Oncology, 2021.
Interests
Pediatric neuro-oncology; immunotherapy
Services and Specialties
Interests
Immunotherapy; developmental therapeutics; clinical trials
Research Areas
Locations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Novel TCR-like CAR-T cells targeting an HLA∗0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia. Molecular Therapy-Methods & Clinical Development. 2021; 23:296-306.
Considerations when treating high-grade pediatric glioma patients with immunotherapy. Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders. 2021; 21:205-219.
Transferrin conjugated nontoxic carbon dots for doxorubicin delivery to target pediatric brain tumor cells. Nanoscale. 2016; 8:16662-16669.
A novel POT1-TPD presentation: A germline pathogenic POT1 variant discovered in a patient with newly diagnosed posterior fossa ependymoma. Cancer genetics. 2025; 292-293:38-43.
Isotretinoin has no effect on event-free survival across high-risk medulloblastoma molecular groups when added to maintenance: A secondary analysis of the Children's Oncology Group ACNS0332 data. Neuro-Oncology Advances. 2025; 7:vdaf054.
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions. Clinical Cancer Research. 2025; 31:561-572.
MDB-86. ISOTRETINOIN HAS NO EFFECT ON EVENT FREE SURVIVAL ACROSS HIGH-RISK MEDULLOBLASTOMA MOLECULAR SUBGROUPS WHEN ADDED TO MAINTENANCE CHEMOTHERAPY: A SECONDARY ANALYSIS OF THE CHILDREN’S ONCOLOGY GROUP ACNS0332 DATA. Neuro-Oncology. 2024; 26:0.
PATH-46. A NOVEL POT1-TPD PRESENTATION: A GERMLINE POT1 MUTATION DISCOVERED IN A PATIENT WITH NEWLY DIAGNOSED POSTERIOR FOSSA EPENDYMOMA. Neuro-Oncology. 2023; 25:v178.
Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica. 2021; 142:859-871.
Biological Treatments of Neurofibromatosis Type 2 and Other Skull Base Disorders. Otolaryngologic Clinics of North America. 2021; 54:789-801.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey